stockrowGyre Therapeutics, Inc.
GYRE Healthcare Biotechnology
- Revenue
- +7.75%
- EPS
- −200.0%
- Free cash flow
- −129.9%
Quarter to September 2026, against a year earlier
Follow GYRE
Alert me
Gyre Therapeutics, Inc. (GYRE) EV/Sales
As of 6 November 2026, Gyre Therapeutics, Inc. (GYRE) trades at a EV/Sales of 3.5×. Over the past ten years it has ranged from −75.1× (June 2018) to 161× (April 2018); the current reading is higher than 62% of that period. That is below the Biotechnology industry median of 9.0× and in line with the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 4.7× | (51.11%) |
| FY2024 | 9.5× | (29.67%) |
| FY2023 | 13.6× | 169.81% |
| FY2022 | 5.0× | — |
| FY2021 | −1.9× | — |
| FY2020 | 2.2× | — |
| FY2018 | −35.1× | — |
| FY2017 | 16.4× | — |
| FY2016 | −23.2× | — |
| FY2015 | −10.6× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 5.8× | 17.21% |
| Jun 2026 | 5.0× | (1.67%) |
| Mar 2026 | 5.1× | 8.50% |
| Dec 2025 | 4.7× | (19.75%) |
| 34 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PRTCY PureTech Health PLC Sponsored ADR compare | −9.1× |
| ARVN Arvinas, Inc. compare | −0.5× |
| EPRX Eupraxia Pharmaceuticals Inc. compare | n/m |
| CRMD CorMedix Inc compare | 0.7× |
| ASMB Assembly Biosciences, Inc. compare | 0.8× |
| PHAT Phathom Pharmaceuticals, Inc. compare | 1.6× |
| PRTA Prothena Corporation plc compare | 2.6× |
| GYRE Gyre Therapeutics, Inc. | 3.5× |
| OCS Oculis Holding AG compare | 176× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)